Division of Infectious Diseases, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.
Immunology. 2011 Mar;132(3):421-31. doi: 10.1111/j.1365-2567.2010.03382.x. Epub 2010 Nov 23.
Hepatitis C virus (HCV) is remarkably efficient at evading host immunity to establish chronic infection. During chronic HCV infection, interleukin-12 (IL-12) produced by monocytes/macrophages (M/Mφ) is significantly suppressed. Programmed death-1 (PD-1), an inhibitory receptor on immune cells, plays a pivotal role in suppressing T-cell responses during chronic viral infection. To determine whether PD-1 regulates IL-12 production by M/Mφ during chronic HCV infection, we examined the expressions of PD-1, its ligand PDL-1, and their relationship with IL-12 production in M/Mφ from HCV-infected, HCV-resolved, and healthy subjects by flow cytometry. Toll-like receptor (TLR) -mediated IL-12 production by M/Mφ was selectively suppressed, while PD-1/PDL-1 expressions were up-regulated, in HCV-infected subjects compared with HCV-resolved or healthy subjects. Up-regulation of PD-1 was inversely associated with the degree of IL-12 inhibition in HCV infection. Interestingly, the reduced response of M/Mφ from HCV-infected individuals to TLR ligands appeared not to be the result of a lack of the ability to sense pathogen, but to an impaired activation of intracellular janus kinase/signal transducer and activator of transfection (STAT) pathway as represented by inhibited STAT-1 phosphorylation in M/Mφ from HCV-infected individuals compared with HCV-negative subjects. Successful HCV treatment with pegylated interferon/ribavirin or blocking PD-1/PDL-1 engagement ex vivo led to reduced PD-1 expression and improved IL-12 production as well as STAT-1 activation in M/Mφ from HCV-infected individuals. These results suggest that the PD-1 inhibitory pathway may negatively regulate IL-12 expression by limiting STAT-1 phosphorylation in M/Mφ during chronic HCV infection.
丙型肝炎病毒 (HCV) 非常有效地逃避宿主免疫以建立慢性感染。在慢性 HCV 感染期间,单核细胞/巨噬细胞 (M/Mφ) 产生的白细胞介素 12 (IL-12) 受到显著抑制。程序性死亡受体-1 (PD-1) 是免疫细胞上的一种抑制性受体,在慢性病毒感染期间抑制 T 细胞反应中发挥关键作用。为了确定 PD-1 是否调节慢性 HCV 感染期间 M/Mφ 中 IL-12 的产生,我们通过流式细胞术检查了 HCV 感染、HCV 已解决和健康受试者的 M/Mφ 中 PD-1、其配体 PDL-1 的表达及其与 IL-12 产生的关系。与 HCV 已解决或健康受试者相比,HCV 感染患者的 TLR 介导的 IL-12 产生被选择性抑制,而 PD-1/PDL-1 的表达上调。PD-1 的上调与 HCV 感染中 IL-12 抑制的程度呈负相关。有趣的是,与 HCV 感染个体的 M/Mφ 对 TLR 配体的反应降低似乎不是由于缺乏感知病原体的能力,而是由于细胞内 Janus 激酶/信号转导和转录激活剂 (STAT) 途径的激活受损,表现为与 HCV 阴性受试者相比,HCV 感染个体的 M/Mφ 中 STAT-1 磷酸化受到抑制。用聚乙二醇干扰素/利巴韦林成功治疗 HCV 或体外阻断 PD-1/PDL-1 结合导致 HCV 感染个体的 M/Mφ 中 PD-1 表达降低,IL-12 产生和 STAT-1 激活改善。这些结果表明,PD-1 抑制途径可能通过限制 M/Mφ 中 STAT-1 磷酸化来负调节慢性 HCV 感染期间 IL-12 的表达。
PLoS One. 2011-5-26
Viruses. 2024-10-15
Am J Physiol Heart Circ Physiol. 2023-10-1
Front Immunol. 2023
Front Microbiol. 2022-2-11
Pharmaceuticals (Basel). 2021-10-29
Gastroenterology. 2009-9-19
Eur J Immunol. 2009-10